Regulation of the T Cell Response by CD39

被引：150
|
作者：
Takenaka, Maisa C. [1 ]
Robson, Simon [2 ,3 ,4 ]
Quintana, Francisco J. [1 ,5 ]
机构：
[1] Harvard Med Sch, Brigham & Womens Hosp, Ann Romney Ctr Neurol Dis, Boston, MA USA
[2] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Med, Div Gastroenterol, Boston, MA USA
[3] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Med, Div Hepatol, Boston, MA USA
[4] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Med, Div Transplantat, Boston, MA USA
[5] Broad Inst MIT & Harva, Cambridge, MA USA
来源：
TRENDS IN IMMUNOLOGY | 2016年 / 37卷 / 07期
关键词：
ARYL-HYDROCARBON RECEPTOR; ATP-DIPHOSPHOHYDROLASE ACTIVITY; HYPOXIA-INDUCIBLE FACTORS; FIND-ME SIGNAL; EXTRACELLULAR ATP; DENDRITIC CELLS; TRANSCRIPTIONAL REGULATION; DIFFERENTIAL EXPRESSION; ADENINE-NUCLEOTIDES; HIGH-SENSITIVITY;
D O I：
10.1016/j.it.2016.04.009
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
The ectonucleoside triphosphate diphosphohydrolase 1 (ENTPD1, or CD39) catalyzes the phosphohydrolysis of extracellular ATP (eATP) and ADP (eADP) released under conditions of inflammatory stress and cell injury. CD39 generates AMP, which is in turn used by the ecto-5'-nucleotidase CD73 to synthesize adenosine. These ectonucleotidases have a major impact on the dynamic equilibrium of proinflammatory eATP and ADP nucleotides versus immunosuppressive adenosine nucleosides. Indeed, CD39 plays a dominant role in the purinergic regulation of inflammation and the immune response because its expression is influenced by genetic and environmental factors. We review the specific role of CD39 in the kinetic regulation of cellular immune responses in the evolution of disease. We focus on the effects of CD39 on T cells and explore potential clinical applications in autoimmunity, chronic infections, and cancer.
引用
收藏
页码：427 / 439
页数：13
相关论文
共 50 条
  • [41] CD39: A new surface marker of mouse regulatory γδ T cells
    Otsuka, Atsushi
    Hanakawa, Sho
    Miyachi, Yoshiki
    Kabashima, Kenji
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2013, 132 (06) : 1448 - 1451
  • [42] Regulation of immune responses through CD39 and CD73 in cancer: Novel checkpoints
    Baghbani, Elham
    Noorolyai, Saeed
    Shanehbandi, Dariush
    Mokhtarzadeh, Ahad
    Aghebati-Maleki, Leili
    Shahgoli, Vahid Khaze
    Brunetti, Oronzo
    Rahmani, Shima
    Shadbad, Mahdi Abdoli
    Baghbanzadeh, Amir
    Silvestris, Nicola
    Baradaran, Behzad
    LIFE SCIENCES, 2021, 282
  • [43] CD39 is a catalyst for immune modulation
    Dwyer, Karen
    Deaglio, Silvia
    Friedman, David
    Enjyoji, Keiichi
    Usheva, Annyn
    Erat, Anna
    Chen, Jiang-Fan
    Strom, Terry
    Robson, Simon
    IMMUNOLOGY AND CELL BIOLOGY, 2006, 84 (03): : A28 - A28
  • [44] Identification of CD39 as a Marker for the Circulating Malignant T-Cell Clone of Sezary Syndrome Patients
    Bensussan, Armand
    Janela, Baptiste
    Thonnart, Nicolas
    Bagot, Martine
    Musette, Philippe
    Ginhoux, Florent
    Marie-Cardine, Anne
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2019, 139 (03) : 725 - 728
  • [45] The Role of CD39 in Ovarian Cancer
    Brauneck, F.
    Witt, M.
    Oliveira-Ferrer, L.
    Sturmheit, T.
    Bokemeyer, C.
    Menzel, S.
    Fiedler, W.
    Wellbrock, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 72 - 72
  • [46] IL-12 and IL-27 Promote CD39 Expression on CD8+T Cells and Differentially Regulate the CD39+CD8+T Cell Phenotype
    Gerhardt, Lara
    Hong, Megan M. Y.
    Yousefi, Yeganeh
    Figueredo, Rene
    Vareki, Saman Maleki
    JOURNAL OF IMMUNOLOGY, 2023, 210 (10): : 1598 - 1606
  • [47] Structure and function of ectoapyrase (CD39)
    Wang, TF
    Handa, M
    Guidotti, G
    DRUG DEVELOPMENT RESEARCH, 1998, 45 (3-4) : 245 - 252
  • [48] CD39+T regulatory cell reconstitution in MS patients with different CD39 gene polymorphisms undergoing autologous HSCT: A Preliminary Study
    Hendrawan, K.
    Ford, C.
    Khoo, M.
    Zaunders, J.
    Molloy, T.
    Ma, D.
    Moore, J.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (03) : NP18 - NP18
  • [49] CD39 EXPRESSION IN GLIOBLASTOMA TUMOR MICROENVIRONMENT DOES NOT AFFECT SURVIVAL OR T-CELL EXHAUSTION
    Zheng, Allison
    Pappu, Ananya
    Gill, Sabraj
    Stelter, Isabella
    Aghi, Manish
    NEURO-ONCOLOGY, 2022, 24 : 279 - 280
  • [50] A Novel T-cell Population Expressing the Ectoenzymes CD38 and CD39 is Associated with Melanoma Patient Non-Response to Immunotherapy.
    Mitra, Ankita
    Woods, David M.
    Rao, Anjali
    Laino, Andressa S.
    Winters, Aidan
    Yanai, Itai
    Chattopadhyay, Pratip K.
    Weber, Jeffrey S.
    CANCER IMMUNOLOGY RESEARCH, 2021, 9 (02)
12345